What is the difference between a generic and a biosimilar?

A generic shows bioequivalence — the same active ingredient delivered the same way. A biosimilar shows no clinically meaningful difference, usually requiring comparative clinical studies.

Why can peptides use the generic route?

At 40 residues or fewer they can be synthesised and characterised completely, so sameness can be established analytically.

Can a synthetic generic reference a recombinant product?

Yes. The FDA accepts sameness demonstrated across manufacturing routes, because it attaches to the molecule rather than the process.

Research & Regulatory News

Two Pathways, Two Timescales

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

A generic drug demonstrates bioequivalence — the same active ingredient delivered at the same rate and extent. A biosimilar must demonstrate no clinically meaningful difference from its reference, usually requiring comparative clinical studies. Peptides of 40 residues or fewer take the first route.

Key facts

Generic route: ANDA — bioequivalence
Biosimilar route: Comparative demonstration of similarity
Deciding factor: The 40-amino-acid threshold
Semaglutide: 31 residues — generic route
Consequence: Faster entry, steeper price falls
Cross-route sameness: Synthetic may reference rDNA-origin

What bioequivalence actually requires

Showing that the proposed product delivers the same active ingredient into the body at the same rate and to the same extent as the reference. It is a pharmacokinetic demonstration, generally achievable without new efficacy trials, because the active ingredient is identical and identity can be established analytically.

Why biosimilars cannot do that

A large protein made in living cells is not identical between manufacturers. Glycosylation patterns and higher-order structure depend on the cell line and process, so no two products are the same molecule in the way two batches of a synthesised peptide are. Similarity therefore has to be demonstrated rather than asserted, which usually means comparative clinical work.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

Why a peptide escapes that

Because at 40 residues or fewer it can be synthesised chemically and characterised completely — sequence, mass, purity, impurity profile, all measurable. Where two products can be shown to be the same molecule by analysis, the reason for demanding comparative clinical evidence falls away.

The cross-route provision

The FDA accepts that an applicant may demonstrate a proposed synthetic peptide is the same as the active ingredient in a previously approved peptide of recombinant DNA origin. So a generic made by chemical synthesis can reference an innovator made in cells. Sameness attaches to the molecule, not to the process — which is a substantive regulatory position rather than a technicality.

What that means commercially

Entry measured in months rather than years, and by many manufacturers at once rather than a few. That is the mechanism behind the reported price falls of 70 to 90 per cent in India within weeks of expiry. Biosimilar markets do not behave that way, because the barrier to entry is far higher.

Where the line sits in this catalogue

Semaglutide at 31 residues, tirzepatide and retatrutide at 39 — all on the drug side. IGF-1 LR3 at 83 residues would be handled as a biologic, which is consistent with its recombinant production and with the impurity profile discussed elsewhere on this site. None of this applies to research material, which holds no authorisation and no classification.

Quick reference

	Generic drug	Biosimilar
Must show	Bioequivalence	No clinically meaningful difference
Clinical studies	Usually not required	Usually required
Applies to	≤40 residues	>40 residues
Typical entry	Months, many entrants	Years, few entrants

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What is the difference between a generic and a biosimilar?: A generic shows bioequivalence — the same active ingredient delivered the same way. A biosimilar shows no clinically meaningful difference, usually requiring comparative clinical studies.
Why can peptides use the generic route?: At 40 residues or fewer they can be synthesised and characterised completely, so sameness can be established analytically.
Can a synthetic generic reference a recombinant product?: Yes. The FDA accepts sameness demonstrated across manufacturing routes, because it attaches to the molecule rather than the process.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum